KNSA

Kiniksa Pharmaceuticals International, plc Healthcare - Drug Manufacturers - Specialty & Generic Investor Relations →

NO
111.5% ABOVE
↓ Approaching Was 111.9% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $21.79
14-Week RSI 60
Rel. Volume (14w) This week's trading vs. the 14-week average 1.5x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.01

Kiniksa Pharmaceuticals International, plc (KNSA) closed at $46.08 as of 2026-03-20, trading 111.5% above its 200-week moving average of $21.79. The stock is currently moving closer to the line, down from 111.9% last week. The 14-week RSI sits at 60, indicating neutral momentum.

Trading volume is running at 1.5x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.01 ratio) is neutral — neither side is clearly dominating.

Over the past 360 weeks of data, KNSA has crossed below its 200-week moving average 9 times. On average, these episodes lasted 18 weeks. Historically, investors who bought KNSA at the start of these episodes saw an average one-year return of +7.9%.

With a market cap of $3.5 billion, KNSA is a mid-cap stock. The company generates a free cash flow yield of 2.8%. Return on equity stands at 11.7%. The stock trades at 6.2x book value.

Share count has increased 9.5% over three years, indicating dilution.

Over the past 7 years, a hypothetical investment of $100 in KNSA would have grown to $297, compared to $245 for the S&P 500. That represents an annualized return of 16.8% vs 13.6% for the index — confirming KNSA as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

Free cash flow has been growing at a 188.1% compound annual rate, with 4 consecutive years of positive cash generation.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: KNSA vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After KNSA Crosses Below the Line?

Across 9 historical episodes, buying KNSA when it crossed below its 200-week moving average produced an average return of -2.1% after 12 months (median +3.0%), compared to +25.2% for the S&P 500 over the same periods. 56% of those episodes were profitable after one year. After 24 months, the average return was +15.8% vs +36.0% for the index.

Each line shows $100 invested at the moment KNSA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Historical Touches

KNSA has crossed below its 200-week MA 9 times with an average 1-year return of +7.9% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Apr 2019Feb 20204069.0%+23.0%+197.3%
Mar 2020Mar 2020321.3%+49.6%+196.9%
Aug 2020Oct 202069.8%-22.6%+179.0%
Oct 2020Nov 2020411.2%-33.7%+194.3%
Mar 2021Mar 202112.5%-41.9%+176.1%
Apr 2021Nov 20228248.8%-28.2%+194.8%
Jan 2023May 20231924.2%+34.4%+228.0%
Jun 2023Jul 202324.3%+32.6%+227.3%
Nov 2023Nov 202313.0%+58.3%+219.1%
Average18+7.9%

Frequently Asked Questions

Is KNSA below its 200-week moving average?

No. Kiniksa Pharmaceuticals International, plc (KNSA) is currently 111.5% above its 200-week moving average of $21.79. It would need to fall to $21.79 to cross below the line.

What is KNSA's 200-week moving average price?

Kiniksa Pharmaceuticals International, plc's 200-week moving average is $21.79 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when KNSA drops below its 200-week moving average?

KNSA has crossed below its 200-week moving average 9 times in our data. On average, buying at that moment produced a one-year return of +7.9%. These dips have historically been decent entry points. These episodes lasted 18 weeks on average.

Is KNSA a good value right now?

Here's what our data says about KNSA as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 60. Free cash flow yield is 2.8%. Return on equity is 11.7%. Price-to-book is 6.2x. This is not a buy or sell recommendation — always do your own research.

How does KNSA compare to the S&P 500?

Over the past 7 years, $100 invested in KNSA would have grown to $297, compared to $245 for the S&P 500. That's 16.8% annualized vs 13.6% for the index. KNSA has outperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-03-20